Fundraising Fox
LimmaTech Biologics
acquired by LillyFounded 2015 · 57 employees on LinkedIn · 6 known investors
Find your way into LimmaTech Biologics
Sign up to see every warm intro you have to LimmaTech Biologics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the LimmaTech Biologics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
LimmaTech develops vaccine technologies and programs designed to combat antimicrobial-resistant pathogens and prevent severe infections. The company uses proprietary vaccine platform technology and engineered microorganisms to create vaccine solutions addressing emerging infectious diseases and antimicrobial resistance.
Investors · 6
How we know: Adjuvant Capital's portfolio page · a partner's Signal profile · funding news · biospace.com · Not right? Tell us
How we know: Andera Partners's portfolio page · Not right? Tell us
How we know: Novo Holdings's portfolio page · Not right? Tell us
How we know: funding news · biospace.com · Not right? Tell us
Also in the syndicate · 2
Funding
SEC filings, press & company announcements$3M disclosed across 1 of 2 rounds · 2023–2024
- $3MSeries AFeb 2024 · 2 sources
Adjuvant Capital (lead), AXA IM Alts (lead), Novo Holdings REPAIR Impact Fund (lead), Tenmile
Source ↗ - Undisclosed amountSeries AOct 2023Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does LimmaTech Biologics do?
- LimmaTech develops vaccine technologies and programs designed to combat antimicrobial-resistant pathogens and prevent severe infections. The company uses proprietary vaccine platform technology and engineered microorganisms to create vaccine solutions addressing emerging infectious diseases and antimicrobial resistance.
- Who are LimmaTech Biologics's investors?
- LimmaTech Biologics's investors include Adjuvant Capital, Andera Partners, Novo Holdings, Tenmile.
- How much funding has LimmaTech Biologics raised?
- LimmaTech Biologics has disclosed $3M raised across 1 of its 2 known rounds.
- Who acquired LimmaTech Biologics?
- LimmaTech Biologics was acquired by Lilly.